Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CTSC | P53634 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964545 | 1.00 | AKR1C3 (0.47) | AKR1C3SOS1CTSKCTSCHRH3 | |
| SCHEMBL29964783 | 1.00 | AKR1C3 (0.47) | AKR1C3SOS1CTSKCTSCHRH3 | |
| SCHEMBL14862707 | 0.85 | AKR1C3 (0.49) | AKR1C3L3MBTL3ABL1L3MBTL1PHGDH | |
| SCHEMBL15551986 | 0.85 | SOS1 (0.41) | SOS1CTSKCTSCHRH3L3MBTL1 | |
| SCHEMBL30644253 | 0.85 | AKR1C3 (0.47) | AKR1C3SOS1CTSKCTSCHRH3 | |
| SCHEMBL15551984 | 0.85 | SOS1 (0.41) | SOS1CTSKCTSCHRH3L3MBTL1 | |
| SCHEMBL31276654 | 0.85 | AKR1C3 (0.47) | AKR1C3SOS1CTSKCTSCHRH3 | |
| SCHEMBL16440196 | 0.85 | AKR1C3 (0.47) | AKR1C3SOS1HRH3L3MBTL1 | |
| SCHEMBL24680803 | 0.82 | AKR1C3 (0.49) | AKR1C3HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL23328988 | 0.81 | LMNA (0.43) | SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | AKR1C3 2993/4885SOS1 1828/4885CTSK 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.